
2026 is the year of not only AI really taking over (are you feeling it?) but also the Oral GLP-1 Competition heating up. 🔥
Novo just launched their Wegovy pill and hit over 18,000 prescriptions within its first two weeks. Lilly's likely approval comes in April. And last week, Corxel raised $287M to fund a third contender.
The stakes are obvious: whoever cracks the pill wins the mass market. But there's a problem nobody's solved yet—and it's not efficacy. It's keeping the drug down.
